The Role of EGFR Inhibitors in the Treatment of Metastatic Anal Canal Carcinoma: A Case Series

Table 1

Details on the treatment of the three ACC patients receiving anti-EGFR agents.

Pt	Location at diagnosis	1st line	Rec site	TTP (wks)	2nd line	Rec site	TTP (wks)	3rd line	Rec site	TTP (wks)	Treatment after anti-EGFR agent
1	Anorectal junction– iliac lymph nodes	Cis-5-FU-RT	Abdominal, inguinal LN	5	Cetux-MMC—10 courses (week 12 : MMC discontinued)	Left inguinal mass	20	Cetux-Iri; (11 courses)	inguinal LN	22	RT-modified FOLFOX-7—the patient died 3 months later
2	Rectum, liver, abdominal LN, bones	5-FU- MMC	Liver	6	Cis plus Iri	Liver, bone metastases	8	Cetux; (8 courses)	Skeletal pain increased	8	Palliative RT for bone pain–no PD visible in scanning or CT–patient did not wish to continue treatment
3	Anal sphincter T3N0M0	MMC, 5-FU, and RT	Abdominal lymph nodes	81	FOLFOX	Abdominal LN	5	Panitumumab (after HSR to cetuximab) (12 courses)	Local recurrence	6	RT

Cetux: cetuximab, Cis: cisplatin, CT: computed tomography scans, HSR: hypersensitivity reaction, Iri: irinotecan, LN: lymph nodes, MMC: mitomycin C, PD: disease progression, Rec site: site of recurrence, RT: radiotherapy, wks: weeks.